3 Stocks Targeting Weight Loss Market With Cannabinoid-Based Therapies

The obesity market has garnered much interest lately, propelled by the success of GLP-1 therapies Wegovy and Zepbound, marketed by pharma giants Novo Nordisk (NVO) and Eli Lilly (LLY) , respectively. This space is growing at an exponential pace and is expected to reach $100 billion by 2030.The soaring demand for weight-loss drugs has pushed companies to innovate beyond GLP-1s. One emerging area of interest is cannabinoid (CBD)-based therapies, which may unlock new mechanisms for managing weight and metaboli ...